The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Rachel Schiff, Hazel M. Weir et al.|British Journal of Cancer|2018Cited by 65
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasisMario Giuliano, Meghana V. Trivedi, Mothaffar F. Rimawi et al.|Breast Cancer Research|2015Cited by 57
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancerNoor Mazin Abdulkareem, Meghana V. Trivedi, Raksha R. Bhat et al.|The FASEB Journal|2021Cited by 25
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Rachel Schiff, Resel Pereira et al.|Cell Reports|2023Cited by 20
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft modelsJamunarani Veeraraghavan, Rachel Schiff, Carolina Gutiérrez et al.|npj Breast Cancer|2021Cited by 11